Demographic Data |
Relation to Proband |
proband |
Age at Sampling |
8 YR |
Sex |
Male |
Age of Onset(If not a control) |
9 MO |
Age at Diagnosis(If not a control) |
2 YR |
Hispanic or Latino/Not Hispanic or Latino |
Not Hispanic/Latino |
Racial Category |
White |
Country |
USA |
|
Data Elements |
Clinical Element Type: General NIGMS Catalog Remarks |
(Baseline) |
Mutation Information |
Gene, variant, consequence, and exon number: |
TCF4, C.1841C>T (P.A614V), MISSENSE, EXON 18 |
Zygosity: |
Heterozygous |
Age of Symptom Onset and Age at Diagnosis |
Age of Symptom Onset: |
9 MONTHS |
Age at Diagnosis: |
2 YEARS |
In Utero History Information |
|
|
Birth History Information |
|
|
Dysmorphic Features |
|
Strabismus
|
Neurological Symptoms |
|
|
Optical and Audiological Symptoms |
|
|
Musculoskeletal Symptoms |
|
|
Developmental Milestones |
|
|
Additional Information: |
DEVELOPMENTAL DELAY |
Gastrointestinal Symptoms |
|
|
Genitourinary Symptoms |
|
|
Respiratory and Cardiovascular Symptoms |
|
|
Cognitive and Behavioral Symptoms |
|
|
Additional Information |
Testing Performed |
Metabolic, Hematologic, and Endocrinologic Testing: |
URINE CREATININE: NORMAL
URINE ORGANIC ACID: NORMAL
PLASMA AMINO ACIDS: UNREMARKABLE
ACYCLCARNITINE: NORMAL |
Uncategorized Testing: |
ANGELMAN SYNDROME CRITICAL REGION: NORMAL METHYLATION
CGG REPEAT EXPANSION IN FMR1 GENE: NEGATIVE
KARYOTYPING AND MICROARRAY: NORMAL MALE |
Treatments and Assistive Devices |
|
Occupational therapy Physical therapy Speech therapy Orthotics
|
Surgeries |
EYE SURGERY TO CORRECT STRABISMUS |
Medications |
Family History |
Remarks |
Clinically affected; heterozygous for a missense de novo variant of unknown significance c.1841C>T (p.A614V) in exon 18 of TCF4 gene; homozygous for benign variant IVS8+137G>A in ZEB2 gene; onset of symptoms at 9 months of age when milestones were not met; diagnosed at 2 years of age; tested for: urine creatinine, plasma amino acids profile is unremarkable, normal acyclcarnitine profile, and normal urine organic acid; normal methylation pattern in AS critical region; negative for CGG repeat expansion in FMR1 gene; tested by karyotyping and microarray; treatment and management: physical therapy, occupational therapy, orthotics, speech language therapy (regularly, 1+ x/week); eye surgery to correct strabismus; same subject as GM26023 (fibroblast). |